Pharmacia Zyvox
Executive Summary
In the first week following its April 18 approval, Pharmacia finds "a great number of hospital orders [for Zyvox] coming directly to us and bypassing the wholesalers," Exec VP and Head of Global Business Management Carrie Cox said during an April 25 teleconference (1"The Pink Sheet" April 24, p. 4). Pricing for Zyvox I.V. therapy has been set at $115/day, which Pharmacia said is less than half the cost of daily therapy with Aventis' injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin). Zyvox oral therapy will cost $85/day